Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One day of buying doesn't equate to accumulation, we need to see that for a week straight.
this one has been getting accumulated.. i think it will go big on a pr someday
Dff agree with u and have built a nice position here gl
It went along as a non event, but getting caught up on the financials was a huge step in the right direction. Three years of updates is not an easy undertaking and it shows that NANM is trying to become a serious company. How many companies that have been on the pinks for 3 years ever get off it? Not many.
Getting the first contract is always the hardest thing to do especially when you’re on the pinks. I believe that we’ll see a steady PPS increase this year hitting between 20 and 30 cents when the next contract is announced. When that will happen, who knows, but going to the big show last month has to give us good leads. I think things look bright in the future.
I’m not going to say this is the stock you should buy, but take a look at what has been accomplished this past year and make your decision. I have. GLTA
I agree, there is good potential for new customers and large advanced orders. Lets hope we hear more contract news soon.
After checking things I found out that the Health show is the second largest in the world.
I can see news in the future about booked sales. Here is the link.
http://www.arabhealthonline.com/home/
1st Floor
Very nice update. If they can get additional sales from the big show things could get interesting. For the first time in a long time I'm optimistic about our future.
Nano Mask Opens Office in Riyadh, Saudi Arabia Due to Strong Demand for Company's Products
Nano Mask to Exhibit at Arab Health Trade Show at Dubai, UAE In January 2012
FISHKILL, N.Y., Jan. 17, 2012 /PRNewswire/ -- Nano Mask, Inc. (NMI) (Pink Sheets: NANM), a healthcare product development and distribution company focused on emergency and critical care as well as infection control markets, today announced that it has opened a sales, marketing and distribution office in Riyadh, Saudi Arabia to service its customers in the Middle East and to tap into the strong demand for its products in the region. Mr. David Willoughby, NMI's VP, Sales and Marketing, will be stationed in Riyadh over the next 6 to 12 months in order to work closely with NMI's Saudi Arabian partners in developing sales and distribution channels in the region.
NMI previously announced a distribution agreement with a Saudi Arabia-based medical products distributor which will represent NMI's product line on an exclusive basis to: The Kingdom of Saudi Arabia, United Arab Emirates (UAE), Kuwait, Egypt, Morocco, Oman, Algeria, Qatar, Jordan, Bahrain, Sudan, Yemen Lebanon, Yemen and Tunisia.
The Saudi Arabian medical products distributor, having already placed significant orders with NMI, has agreed to order a minimum of more than $2 million over the next four years. The products that will be marketed and sold in the Territory are: NMI's emergency life support and respiratory products (utilizing the company's industry leading patented 2H Filtration Technology), antimicrobial hospital barrier products and NMI's proprietary line of bacteria free enzymatic medical detergents specially formulated for instrument reprocessing.
Separately, NMI announced that it will be exhibiting, in conjunction with its Saudi Arabian partners, its products at Arab Health Trade Show in Dubai, UAE from 1-23-2012 thru 1-26-2012 (http://www.arabhealthonline.com/home/). This is a major event in the Middle Eastern healthcare market and will provide an excellent showcase for NMI products.
About Nano Mask, Inc.
NMI is the inventor of 2H Technology, an advanced dual filtration system which is designed to remove infectious bacteria and virus from airflow systems at extremely high levels of efficiency. In addition to the company's advanced filtration materials and products, NMI also markets a line of innovative infection control products which range from proprietary enzymatic instrument reprocessing solutions to innovative antimicrobial textiles in the United States and internationally.
Forward-looking Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect sales of NMI products. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.
Contact:
For further information:
Ed Suydam
(914) 760-7857
eds@nmihealth.com
if/when we get a mil+ vol day i think it will be a game changer here... g/l!
Ground Floor
It feels like we are on the ground floor price wise and if they can continue with good news and come through with things mentioned in the PR yesterday, it could be a nice ride up. Price moved up quickly yesterday on average volume. With strong buys IMO it could pop quickly.
thats really a great update on business for NANM!!!! we producing income, and soon to be lots more! GOOOOOOOOOO! FINALLY!
Nano Mask Issues Corporate Update
Press Release: Nano Mask, Inc. – 3 minutes 28 seconds agoShare0EmailPrintCompanies:Nano Mask, Inc.RELATED QUOTESSymbol Price Change
NANM.PK 0.03 +0.00
FISHKILL, N.Y., Jan. 12, 2012 /PRNewswire/ -- Nano Mask, Inc. (NMI) (Pinksheets: NANM.PK - News), a materials technology development company focused on health and wellness related markets, today issued the following corporate update:
X-STATIC®- Infection Prevention Textiles™
NMI, in conjunction with its strategic partner Noble Biomaterials, Inc., has developed a host of new products incorporating Noble's X-STATIC® silver antimicrobial technology. X-STATIC® is clinically proven to eliminate 99% of bacteria directly on the fabrics, providing comprehensive, continuous and permanent antimicrobial protection.
Hospital acquired infection is a major problem worldwide and by offering a whole suite of products to combat this problem, NMI is positioning itself to be a participant in this rapidly growing market. Fabrics made with X-STATIC® fibers are flexible, with the natural look and feel of traditional textiles, while offering all the benefits of pure silver. The product line consists of professional and patient wear, bed linens, cubical curtains and customized window and wall coverings. The products are now available globally.
RespAide™
NMI will reintroduce RespAide, a state-of-the-art cardio-pulmonary resuscitation (CPR) mask, to the market. RespAide is designed to minimize the potential for transmission of contagious diseases during the administration of CPR and has been granted FDA 510K approval as a Class II medical device. NMI has contracted an Arizona-based company to manufacture the product and has been taking pre-orders for the product from both U.S. and international customers. NMI expects to formally relaunch RespAide in February 2012.
SEC Reporting Progress
NMI has been diligently working to bring its Securities and Exchange Commission filings current and expects to achieve this objective by the end of January 2012.
Sales
In the last six months of 2011 NMI received purchase orders of approximately $ 500,000 and shipped approximately $ 250,000 of product; most of the balance of the purchase orders is expected to ship within the next 30 days. The products on which purchase orders have been received are: products powered by X-STATIC antimicrobial fabric technology, enzymatic detergents, N99 ViraMask, RespAide and disposable cubicle curtains.
About Nano Mask, Inc. (http://nmihealth.com)
We are a healthcare product development and distribution company providing innovative and cost effective emergency and critical care and infection control products to a variety of market segments within the healthcare industry. Our customers range from hospitals, emergency services, surgery centers, long-term care facilities, nursing homes and other clinical settings throughout the healthcare continuum. Today, the fundamental principles that guided the development of our emergency and critical care products through to our infection control products remain a constant. They define our commitment to developing products that function the way they are intended, are manufactured to the very highest standards, achieve benchmark levels of performance, inspire confidence with their use, protect the health of those who use them and ultimately save lives.
About Noble Biomaterials, Inc. (www.InfectionPreventionTextiles.com)
Noble Biomaterials, Inc. is a global leader in bacterial management solutions. Noble develops, manufactures, sells and markets advanced antimicrobial technologies designed to manage all forms of bacterial contamination for medical, defense, industrial and consumer markets.
Forward-looking Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in manufacturing and distribution may affect the planned timeline for initiating actual sales of the product. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.
Contact:
For further information:
Ed Suydam
(914) 760-7857
eds@nmihealth.com
the mm's never do.. only we have to lol
absolutely!! Thought I would have taken out HDSN but hes not showing his hand
filings...OR contracts ;)
Interesting, gonna get a smaller starter here I think
10Q filed, "At January 4, 2012, there were outstanding 80,753,864 shares of the Registrant's Common Stock, $.001 par value."
added .028/.03's
looking great .. large bid at .06, recent insider buying, 52wk high is .07 fwiw
form 4, cmo bought 98k at .05!
wow.. was in a long meeting today and just saw the selloff here.. will have to try to free up cash now that it's back down here
10k filed Dec312009
10q filed Jun302009
form4 filed by ceo, gave some shares as bona fide gift
I like the way it held .05, no big sell into it, with some small but steady accumulation. Let's see it break the 52 week high of .07 without any news then I hope for the next finanical update. If we get these things first then some additional sales look for us to be in the mid 20's. JMO
Me too, and we are looking very nice.
my lowest were around .02 but my avg is .03.. i have a pretty sizeable position here ;)
Yep, that's why I loaded .02 when they started the filing catch up, lol.
Hope so. Good luck to you.
Nice to hear from you again Dublesvp:
NANM slowly churning here in the .05-.055 region with pre market buys two days in a row. Could see some hefty gains soon..
Hi silencedogood2011,
It's good to see you again!
I want to see more info on the filings. Once I see that I'll be buying more.
Evenin Lichartin:
The company is getting all back filings finished and is starting to get orders filled. It looks like this company is starting to get back on its feet. This is a long play for me and will buy all dips.
Long term I am seeing over a dollar if they continue to get large oreders and keep the share structure the same.
still holding my .04, I hope we hit .10 soon
Very nice close. Glad I started buying when it was real cheap.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
405
|
Created
|
10/22/04
|
Type
|
Free
|
Moderators |
Level 2 View - Not Realtime!
Q. What is swine flu?
A. Swine influenza, or flu, is a contagious respiratory disease that affects pigs. It is caused by a type-A influenza virus. Outbreaks in pigs occur year-round.
The most common version is H1N1. The current strain is a new variation of an H1N1 virus, which is a mix of human and animal versions.
EMFP .49...this is damn important for EMFP...Itochu is an $85 BILLION Corp-worldwide...they will sell at least thru out Asia...not just Japan...as bird flu is becoming a very real threat over there. This is part 1...part 2 are the results of the military testing due soon...see next PR below this one...the testing is just pro forma IMO...this will be a helluva one two punch and should finally get EMFP moving:
B: Itochu Techno Chemical Obtains Regulatory Approval to Import and Sell Emergen
y Filtration Products' Respiratory Devices in Japan
HENDERSON, Nev., Oct 21, 2004 (BUSINESS WIRE) -- Emergency Filtration Products
Inc. (EFP) (OTCBB: EMFP) today announced that its partner, Itochu Techno
Chemical Inc., has obtained a Certificate of Import and a Certificate of Sale
from Koseisho (the Japanese Ministry of Health and Welfare, akin to the U.S.
FDA) to immediately begin importing and selling EFP's RespAide, Vapor Isolation
Valve and Series One Breathing Circuit Filter products in Japan.
EFP and Itochu Techno Chemical have been collaborating for over 18 months in
order to help bring EFP's products to market in Japan, as well as preparing a
feasibility study to expand distribution to other Asian countries, with possible
global expansion. After filing an application with Koseisho on Feb. 27, 2004,
the two companies began working on a distribution agreement that would govern
the sale of EFP products to Itochu Techno Chemical and other related companies.
EFP expects to enter into a long-term distribution agreement in the near future.
"We are extremely pleased to have our products cleared for launch in Japan,"
said Douglas K. Beplate, president, EFP. "We would like to thank our partners at
Itochu Techno Chemical for all of their hard work with regard to the application
made with Koseisho and especially with respect to their meticulous and
painstaking approach to assuring the success of our products in the Japanese
market place." Beplate went on to add, "EFP is highly confident that Itochu
Techno Chemical's expertise will not only pay off in the rapidly growing $300
million Japanese market for respiratory products, but will also lead to success
in other Asian countries and beyond."
Itochu Techno Chemical (http://www.techno-chemical.com/ is a subsidiary of
Itochu Corp.
Itochu Corp. (http://www.itochu.co.jp/main/index.html), one of the world's
largest trading companies with 2003 revenues in excess of $85 billion, ranked
11th in the world by revenues, according to Forbes magazine. Itochu is a
globally integrated corporation with offices in over 80 countries and operations
that cover a broad spectrum of industries.
About Emergency Filtration Products Inc.
EFP (http://www.emergencyfiltration.com/) is an air filtration products
manufacturer whose patented 2H Technology(TM) filter system has produced
filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027
microns. Its initial products were developed for the medical market: the Vapor
Isolation Valve(TM) and RespAide(R) CPR Isolation Mask used for resuscitation of
respiratory/cardiac arrest cases; and the 2H Breathing Circuit Filter for
ventilators, respirators and anesthesia circuitry. Each has received FDA
approval. The company also markets an Automated External Defibrillator Prep Kit
featuring RespAide; and the NanoMask(R), a nanotechnology enhanced environmental
mask. In addition to filtration products, the company supplies Superstat(R), a
modified hemostatic collagen, to the U.S. military for surgery and extreme wound
care.
B: Center for Commercialization of Advanced Technology -- CCAT --
B: Center for Commercialization of Advanced Technology -- CCAT -- Awards Emergen
HENDERSON, Nev., Sep 14, 2004 (BUSINESS WIRE) -- Emergency Filtration Products,
Inc. (EFP) (OTCBB:EMFP) announces that it has been awarded a Prototype
Development/Testing/Evaluation Grant (PDT&E) to develop a testing protocol for
filter media on behalf of the U.S. Military. As part of this project, EFP will
begin testing its licensed nano-enhanced filter media at Edgewood Chemical
Biological Center in Edgewood, Maryland within the next few weeks. The testing
and evaluation process is expected to take approximately one month to complete,
following which (assuming positive testing results), EFP expects to sub-license
its nano-enhanced filter media to a Department of Defense approved manufacturer
to enhance existing filtration products that are currently used by the U.S. Air
Force, Army and Navy, as well as to commence development of new product
applications that will serve to better protect U.S. Military personnel.
"The award of the PDT&E grant from CCAT to develop a standard filter media
testing protocol for the U.S. Military is a milestone for our company," said
Douglas K. Beplate, President, EFP. "While we originally expected to begin
testing for the U.S. Air Force last month, we have been requested to have our
filter technology tested for all branches of the Military simultaneously." Mr.
Beplate went on to add, "We expect that the testing will not only prove to be
successful, but will also lead to a rapid commercialization of our licensed
nano-enhanced filter media technology which will assist all branches of the U.S.
Military - Army, Air Force and Navy - to incorporate our technology into
applications that will serve the U.S. Military worldwide."
For the past 18 months, EFP has been working in conjunction with U.S. Army
Research, Development & Engineering Command (RDECOM) to test its nano-enhanced
2H filter technology in order to accelerate the commercial development of a
number of filter technology applications and allow for rapid procurement by the
U.S. Department of Defense. RDECOM has been examining how to apply the company's
filter technology to a large number of potential applications, including, but
not limited to: biohazard masks, transportation (aircraft, tanks, armored
personnel carriers) and buildings (military, industrial, office and
residential). The program has conducted a number of cost and user needs
analyses, economic analyses and technical viability studies of EFP's proprietary
licensed 2H Filter technology. Over 1,000 potential applications of EFP's filter
technology have been identified by RDECOM.
About RDECOM:
http://www.rdecom.army.mil/index.html
MISSION -- Get the right integrated technologies into the hands of warfighters
quicker.
VISION -- To be recognized as the preeminent world leader in research,
development and engineering of systems, whose hallmark is transitioning the
right technology in the shortest time to our Soldiers.
INTENT -- The Commanding General of the U.S. Army Materiel Command (AMC)
established the U.S. Army Research, Development & Engineering Command (RDECOM),
as a new major subordinate command within AMC. This new command will restructure
core in-house capabilities now so we can fully exploit the enormous potential
that resides in research activities around the world. RDECOM will respond
rapidly by integrating, maturing and demonstrating emerging technologies to
field the right equipment, in the shortest time, for our Soldiers.
About ECBC:
http://www.ecbc.army.mil/
ECBC is the nation's principal research and development center for chemical and
biological defense. Tracing its roots back to 1917, ECBC leverages more than 85
years of experience with live agent to develop and enhance defense systems.
ECBC seeks opportunities to develop partnerships with industry, academia and
state and local governments to continue achieving major technological advances
for national defense, civilian protection and industrial competitiveness.
Complimenting these efforts, the Center offers several unique facilities that
provide full life-cycle support to chemical and biological protection, detection
and monitoring capabilities.
About CCAT:
The CCAT (http://www.ccatsandiego.org/index.shtml)- supported by Congress and
funded by the Department of Defense - is a public-private collaborative
partnership between academia, industry, and government. Partners include San
Diego State University (SDSU) Foundation and Entrepreneurial Management Center,
the University of California, San Diego (UCSD) Jacobs School and UCSD CONNECT,
and Lockheed Martin ORINCON Technologies, Inc. with support from the Space and
Naval Warfare Systems Center, San Diego. The consortium-style CCAT intends to
bridge the gap that exists between the generators of technology, the Department
of Defense and the commercial marketplace. EFP will also be working in
conjunction with the Office of Technology Transfer and Commercialization (OTTC)
at California State University, San Bernardino (http://ottc.csusb.edu/), a CCAT
partner on this project.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |